Exhibit 99.1
PDS Biotechnology to Present at the 12th Annual LD Micro Main Event
Princeton, NJ, December 3, 2019 - PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical stage immuno-oncology company with a broad pipeline of novel products based
on the company’s proprietary Versamune® T-cell activating technology, today announced that Dr. Frank Bedu-Addo, President and Chief Executive Officer, is scheduled to present the company’s upcoming clinical trials and recent clinical data
demonstrating the potential of the Versamune®-based products to overcome key limitations of current cancer immunotherapy at the 12th Annual LD Micro Main Event being held on December 10-12, 2019 at the Luxe Sunset Boulevard Hotel in Los
Angeles, CA.
Event: 12th Annual LD Micro Main Event
Format: Presentation & 1x1 Meetings
Date: Wednesday, December 11, 2019
Time: 1:40pm PT
Location: Luxe Sunset Boulevard Hotel, Los Angeles, CA: Track
3
About PDS Biotechnology
PDS Biotechnology is a clinical-stage immuno-oncology company with a broad pipeline of novel products based on the company’s proprietary Versamune® T-cell activating
technology. The Versamune® platform effectively delivers tumor-specific antigens for in-vivo uptake and processing, while also activating a critical immunological pathway, the type 1 interferon pathway, thus resulting in the production of potent
tumor-specific killer T-cells. Using Versamune®, PDS Biotechnology is engineering therapies designed to better recognize cancer cells and break down their defense systems to effectively attack and destroy tumors. PDS Biotechnology’s pipeline
combines the Versamune® technology with tumor-specific antigens across several cancer types. To learn more, please visit www.pdsbiotech.com or follow us on
Twitter @pdsbiotech.
Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of
Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements
may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information
currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,”
“expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on
current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors,
including, without limitation: the ability of the Company to integrate Edge and PDS Biotechnology following the merger; the Company’s ability to protect its intellectual property rights; competitive responses to the completion of the merger;
potential adverse reactions or changes to business relationships resulting from the completion of the merger; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations
regarding its plans for future equity financings; the timing for the Company or its partners to initiate the planned clinical trials for its lead assets, PDS0101 and PDS0102; the Company’s interpretation of the results of its Phase 1 trial for
PDS0101 and whether such results are sufficient to support additional trials or the future success of such trials; the successful implementation of the
Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101 and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are
sufficient to support the future success of the Company’s product candidates; the acceptance by the market of the Company’s product candidates, if approved; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug
Administration or other regulatory authority approval of, or other action with respect to, the Company’s product candidates; and other factors, including legislative,
regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere,
including the risk factors included in the Company’s annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company
undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Media & Investor Relations Contacts:
Tram Bui / Alexander Lobo
The Ruth Group
Phone: +1-646-536-7035 / +1-646-536-7037
Email: tbui@theruthgroup.com / alobo@theruthgroup.com